MorphoSys AG
FRA:MOR ISIN:DE0006632003
MorphoSys is a publicly traded biotechnology company focused on the generation of fully human antibodies as a means to discover and develop innovative antibody-based drugs against life-threatening diseases. MorphoSys's goal is to establish HuCAL as the technology of choice for antibody generation in research, diagnostics and therapeutic applications. The Company currently has therapeutic and research alliances with the majority of the world's largest pharmaceutical companies including Bayer-Schering, Boehringer Ingelheim, Centocor/Johnson & Johnson, Novartis, Pfizer and Roche. Within these partnerships, more than 40 therapeutic antibody programs are ongoing in which MorphoSys participates through exclusive license and milestones payments as well as royalties on any end products. Additionally, MorphoSys is active in the antibody research market through its AbD Serotec business unit. The business unit has operations in Germany (Munich), the U.S. (Raleigh, NC) and U.K. (Oxford).
News
MorphoSys AG (PINKSHEETS:MPHSF) MorphoSys AG (FSE: MOR; Prime Standard Segment, TecDAX) will publish its first six months' 2008 results on July 29, 2008 at 7:30 a.m. CEST.
MorphoSys AG (PINKSHEETS:MPHSF) MorphoSys AG (FSE: MOR; Prime Standard Segment, TecDAX) announced today that Astellas Pharma Inc. has exercised a pre-existing option to use MorphoSys's proprietary RapMAT technology for faster antibody optimization as part of the existing technology transfer agreements between the two companies. As a result, Astellas will have access to MorphoSys's RapMAT technology module alongside the existing installation of the Company's proprietary antibody library HuCAL GOLD at Astellas' research site in Tsukuba, Japan. Under the extended agreement MorphoSys will receive annual user fees for the RapMAT technology and continues to receive annual user fees for access to its HuCAL platform. Further financial details were not disclosed.
MorphoSys AG (PINKSHEETS:MPHSF) MorphoSys AG (FSE: MOR; Prime Standard Segment, TecDAX) announced today that Phadia AB, a world leader in autoimmunity and allergy testing, has implemented a series of HuCAL-based recombinant antibodies in its marketed autoimmune tests Varelisa(TM) and EliA(TM). Thereby Phadia becomes the first diagnostic company to introduce recombinant antibodies in an autoimmune screening platform. AbD Serotec, MorphoSys's division for research and diagnostic antibodies, receives license fees and will continuously supply Phadia with recombinant antibody material. Further financial details were not disclosed.
MorphoSys AG (PINKSHEETS:MPHSF) MorphoSys AG (FSE: MOR; Prime Standard Segment, TecDAX) announced today that Boehringer Ingelheim has exercised a pre-existing option to use MorphoSys's proprietary RapMAT technology for faster antibody optimization as part of the existing technology transfer agreement between the two companies. As a result, Boehringer Ingelheim will have access to MorphoSys's RapMAT technology module alongside the existing installation of the Company's proprietary antibody library HuCAL GOLD at Boehringer Ingelheim's research site in Vienna, Austria. Under the extended agreement, MorphoSys will receive annual user fees for the RapMAT technology and for access to its HuCAL platform. Financial details were not disclosed.
MorphoSys AG (PINKSHEETS:MPHSF) Parties Initiate First Fully Human Antibody Programs Targeting Cancer Stem Cells
MorphoSys AG (Frankfurt Stock Exchange: MOR; Prime Standard Segment) today announced the signing of a research collaboration with New Zealand-based Genesis Research and Development Corporation Ltd. (New Zealand Stock Exchange: GEN).
###
5,054 COMPANY PROFILE VIEWS
- This Page Viewed: (Last 7 Days: 18) (Last 30 Days: 59) (Since Published: 5054)
